Poltreg S.A. (PTG.WA)
PLN 36.0
(4.35%)
PLN 36.0
(4.35%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -13.55 Million PLN | -1143.99% |
| 2022 | 1.29 Million PLN | 134.35% |
| 2021 | -3.77 Million PLN | -284.83% |
| 2020 | -982 Thousand PLN | 15.71% |
| 2019 | -1.16 Million PLN | 13.7% |
| 2018 | -1.35 Million PLN | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -3.35 Million PLN | 20.08% |
| 2024 Q2 | -4.94 Million PLN | -47.63% |
| 2023 Q2 | -3.17 Million PLN | -786.31% |
| 2023 Q4 | -4.19 Million PLN | 14.95% |
| 2023 FY | -13.55 Million PLN | -1143.99% |
| 2023 Q1 | -358 Thousand PLN | 47.51% |
| 2023 Q3 | -4.93 Million PLN | -55.37% |
| 2022 FY | 1.29 Million PLN | 134.35% |
| 2022 Q4 | -682 Thousand PLN | -294.3% |
| 2022 Q3 | 351 Thousand PLN | 344.3% |
| 2022 Q2 | 79 Thousand PLN | 108.29% |
| 2022 Q1 | -953 Thousand PLN | 56.88% |
| 2021 Q1 | -360 Thousand PLN | -62.16% |
| 2021 FY | -3.77 Million PLN | -284.83% |
| 2021 Q4 | -2.21 Million PLN | -139.44% |
| 2021 Q3 | -923 Thousand PLN | -276.73% |
| 2021 Q2 | -245 Thousand PLN | 31.94% |
| 2020 Q2 | -229 Thousand PLN | 0.0% |
| 2020 Q3 | -198 Thousand PLN | 13.54% |
| 2020 Q4 | -222 Thousand PLN | -12.12% |
| 2020 FY | -982 Thousand PLN | 15.71% |
| 2020 Q1 | -229 Thousand PLN | 0.0% |
| 2019 FY | -1.16 Million PLN | 13.7% |
| 2018 FY | -1.35 Million PLN | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioceltix S.A. | -13.68 Million PLN | 0.998% |
| BIOTON S.A. | 2.27 Million PLN | 695.648% |
| Captor Therapeutics Spolka Akcyjna | -70.58 Million PLN | 80.802% |
| Mabion S.A. | 41.26 Million PLN | 132.836% |
| Molecure S.A. | -18.3 Million PLN | 25.984% |
| NanoGroup S.A. | -7.88 Million PLN | -71.753% |
| Pharmena S.A. | 28.94 Million PLN | 146.823% |
| Pure Biologics Spólka Akcyjna | -35.69 Million PLN | 62.036% |
| Ryvu Therapeutics S.A. | -92.11 Million PLN | 85.289% |
| Synthaverse S.A. | 4.75 Million PLN | 384.805% |
| Urteste S.A. | -5.58 Million PLN | -142.589% |